{"schema_version":"1","generated_at":"2026-11-11T07:18:57.659Z","data_as_of":null,"url":"https://www.findmykol.com/kol/assaf-moore","json_url":"https://www.findmykol.com/kol/assaf-moore/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"assaf-moore","name":"Assaf Moore","credential":"MD","specialty":"Radiation Oncology","specialty_raw":"Radiation Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Memorial Sloan Kettering Cancer Center","institution_url":"https://www.findmykol.com/institution/memorial-sloan-kettering-cancer-center","city":"New York","state":"NY","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1225646235","orcid":"0000-0002-1502-3729","openalex":"A5028673499"},"summary":"Assaf Moore is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 92 publications with 962 citations (h-index 16).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":92,"cited_by_count":962,"h_index":16,"latest_activity_year":2025,"source":"works"},"prescribing":{"data_year":2022,"areas_total":1,"areas_shown":1,"areas":[{"area":"Genitourinary & hormones","share_pct":100,"classes_total":1,"classes":[{"class":"alpha-Adrenergic Blocker","setting":"prescribed","share_pct":100,"drugs":[{"name":"Tamsulosin Hcl","share_pct":100}],"max_beneficiaries":null}]}],"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Stereotactic Radiotherapy to the Prostate and Pelvic Lymph Nodes for High-Risk and Very High-Risk Prostate Cancer in a Setting with a Hydrogel Spacer: A Toxicity Report","year":2025,"journal":"Cancers","source_url":"https://doi.org/10.3390/cancers17121970","status":"verified"},{"title":"BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer","year":2025,"journal":"Archives of Endocrinology and Metabolism","source_url":"https://doi.org/10.20945/2359-4292-2025-0127","status":"verified"},{"title":"40 Gray in 5 Fractions for Salvage Reirradiation of Spine Lesions Previously Treated With Stereotactic Body Radiotherapy","year":2024,"journal":"Neurosurgery","source_url":"https://doi.org/10.1227/neu.0000000000002889","status":"verified"},{"title":"SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer","year":2024,"journal":"BMC Cancer","source_url":"https://doi.org/10.1186/s12885-024-12165-1","status":"verified"},{"title":"Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time","year":2024,"journal":"British Journal of Cancer","source_url":"https://doi.org/10.1038/s41416-024-02700-z","status":"verified"}],"source":"works"},"similar":[{"name":"Howard Scher","slug":"howard-scher","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/howard-scher","json_url":"https://www.findmykol.com/kol/howard-scher/profile.json"},{"name":"Robert Motzer","slug":"robert-motzer","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/robert-motzer","json_url":"https://www.findmykol.com/kol/robert-motzer/profile.json"},{"name":"Charles Sawyers","slug":"charles-sawyers","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/charles-sawyers","json_url":"https://www.findmykol.com/kol/charles-sawyers/profile.json"},{"name":"Mark Kris","slug":"mark-kris","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/mark-kris","json_url":"https://www.findmykol.com/kol/mark-kris/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2022}},"methodology_url":"https://www.findmykol.com/about#methodology"}